Disclosed herein are compositions and methods for use in reducing lung function inhibition.

The invention relates to methods of treating baldness, treating alopecia, promoting hair growth, and/or promoting hair follicle development and/or activation or stimulation on an area of the skin of a subject (for example, a human) by subjecting said area of the skin to integumental perturbation. Integumental perturbation can be used in combination with other treatments for promoting hair growth. The invention provides devices for integumental perturbation for promoting hair growth, and provides pharmaceutical compositions for use in combination with integumental perturbation for promoting hair growth.

Methods for treating urinary incontinence associated with neurogenic detrusor overactivity (NDO) and for reducing need for or frequency of clean intermittent catherization (CIC) by injecting a clostridial derivative to the bladder of a patient are disclosed.

This invention relates to novel uses of botulinum neurotoxin in treating a disease or condition associated with lipoedema, in particular uses of botulinum neurotoxin in treating pain associated with lipoedema.

A syringe assembly for administration of a neurotoxin, the syringe assembly comprising: a syringe comprising: a clear syringe barrel with dosage markings completely encircling the clear syringe barrel; and a plunger having a plunger body and a clear inverted plunger tip; and a needle assembly comprising a needle and a sealing hub for removably attaching the needle assembly to the syringe, wherein the needle is approximately 0.15 inches to approximately 0.3 inches in length and has a gauge of approximately 27 gauge to approximately 35 gauge.

Disclosed herein is a liquid pharmaceutical composition of botulinum toxin which is improved in stability. It comprises botulinum toxin, polysorbate 20, and methionine and optionally isoleucine. Employing, instead of the animal-derived protein albumin or gelatin, a combination of polysorbate 20 and methionine and optionally isoleucine as botulinum toxin stabilizers, the liquid pharmaceutical composition eliminates the risk of contaminating the body with serum-derived pathogens or microorganisms and can be administered safely to the body. Also, the composition is convenient for use as a direct injection for patients. Superior to conventional compositions employing either detergents or amino acids in terms of the storage stability of botulinum toxin at 25˜37° C. as well as at refrigerated temperatures, the liquid pharmaceutical composition of the present invention is very useful for storing botulinum toxin under an emergency condition such as an environment without maintaining low temperature. The liquid pharmaceutical composition can be readily prepared because it employs a detergent and an amino acid(s) without lyophilization process.

The present specification discloses methods and uses for treating a migraine disorder. The disclosed method comprising extramuscularly administering a Botulinum toxin to an individual in one of more areas of a fronto-fascial layer located in a frontal head region of the individual, one of more areas of a temporoparietal-fascial layer located in a temporal head region of the individual, and one or more areas of an occipito-fascial layer located in an occipital head region of the individual. The disclosed methods and uses further comprise extramuscularly administering a Botulinum toxin to one or more nerve exit points and/or one or more subcutaneous locations in the head and neck as well as one or more sites of an epicranial aponeurosis. The disclosed methods and uses further comprise intramuscularly administering a Botulinum toxin to one or more locations within the left and right Splenius Capitus muscle, the left and right Masseter muscles, the left and right Trapezius muscles, or any combination thereof.

The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.

Disclosed herein are methods and compositions for treatment of skin disorders and diseases using botulinum toxin targeted to nerve ganglia. It has been unexpectedly found that botulinum neurotoxin (BoNT) can decrease the severity of numerous skin disorders by application to nerve ganglia including but not limited to the parasympathetic, sympathetic, and sensory ganglia

Pharmaceutical compositions that stabilize a Clostridial toxin active ingredient are described. The compositions can be liquid or solid compositions, and comprise a surfactant and an antioxidant. In some embodiments, the compositions comprise a surfactant selected from a poloxamer and a polysorbate; an antioxidant selected from methionine, N-acetyl cysteine, ethylenediaminetetraacetic acid and combinations thereof, and, optionally, a tonicity agent and/or a lyoprotector selected from, for example, trehalose, sucrose.